Corient Private Wealth
AUTL

Corient Private Wealth’s Autolus Therapeutics AUTL Stock Holding History

Corient Private Wealth’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,000
Closed -$28.5K – 2006
2022
Q4 		$28.5K Buy
+15,000
New +$37.9K ﹤0.01% 1660

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
OAMG
Odey Asset Management Group London, United Kingdom $381M AUM 45.36% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Corient Private Wealth's AUTL Position: Q1 2023 in Review

Corient Private Wealth sold out of Autolus Therapeutics (AUTL) in Q1 2023, closing a stake of 15,000 shares — an estimated $28.5K sold.

Corient Private Wealth first reported a position in AUTL in Q4 2022 and held it in 1 quarter. The position peaked at $28.5K in Q4 2022. 65 funds tracked by Wall St. Rank hold AUTL as of Q1 2023.

  • Corient Private Wealth reported no remaining Autolus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Corient Private Wealth sold 15,000 Autolus Therapeutics shares in Q1 2023, an estimated $28.5K.
  • Corient Private Wealth first reported a position in Autolus Therapeutics in Q4 2022 and held it in 1 quarter.
  • Corient Private Wealth's Autolus Therapeutics position peaked at $28.5K in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2023.

Based on Corient Private Wealth's 13F filing for Q1 2023, filed 15 May 2023.